Genentech's cobimetinib NDA gets Priority Review

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said FDA accepted for filing and

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE